July 2019
Volume 60, Issue 9
Open Access
ARVO Annual Meeting Abstract  |   July 2019
Effects of a novel photochemical antimicrobial therapy for keratitis with an improved riboflavin conjugate on experimentally induced infectious corneal ulceration in rabbits
Author Affiliations & Notes
  • Ashley Behrens
    Ophthalmology, Johns Hopkins Wilmer Eye Inst, Baltimore, Maryland, United States
  • Andreina Tarff
    Ophthalmology, Johns Hopkins Wilmer Eye Inst, Baltimore, Maryland, United States
  • Rebecca Yee
    Molecular Microbiology & Immunology, Johns Hopkins University, Baltimore, Maryland, United States
  • Ying Zhang
    Molecular Microbiology & Immunology, Johns Hopkins University, Baltimore, Maryland, United States
  • Footnotes
    Commercial Relationships   Ashley Behrens, None; Andreina Tarff, None; Rebecca Yee, None; Ying Zhang, None
  • Footnotes
    Support  NONE
Investigative Ophthalmology & Visual Science July 2019, Vol.60, 5182. doi:https://doi.org/
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Ashley Behrens, Andreina Tarff, Rebecca Yee, Ying Zhang; Effects of a novel photochemical antimicrobial therapy for keratitis with an improved riboflavin conjugate on experimentally induced infectious corneal ulceration in rabbits. Invest. Ophthalmol. Vis. Sci. 2019;60(9):5182. doi: https://doi.org/.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Infectious keratitis is a common cause of visual disability in the world. The increased incidence of drug resistant ocular pathogens has led to explore innovative approaches to combat the stromal melting. Here we describe a new riboflavin conjugate in combination with ultraviolet light A (UVA) in vivo as a novel therapy for this condition.

Methods : The left cornea of thirty-six (n=18 female) New Zealand Albino rabbits (3-5-month-old), was inoculated with a suspension of a multidrug resistant-methicillin resistant Staphylococcus aureus strain (2 x 109CFU/ml). Corneas were randomly divided in: 1) riboflavin conjugate + UVA, 2) riboflavin + UVA, 3) moxifloxacin eyedrops and 4) no-treatment control group. Once corneal ulcer was established, clinical pictures were taken at day 0 (before treatment) and daily after treatment. Eyes were sent for microbiological/histopathological examination at 3h, 24h and 2 weeks. Corneas were assessed for endothelial cell vitality (TUNNEL test) to evaluate safety. P < 0.05 was considered statistically significant.

Results : Clinical improvement was significant with the riboflavin conjugate + UVA compared to the other groups. The difference in the CFU count between the riboflavin conjugate + UVA and other treatments was statistically significant with 0 CFU (P ≤ 0.00243). No endothelial cell damage in the rabbits’ eyes enucleated at 3h, 24h and 2 weeks after the riboflavin conjugate + UVA administration.

Conclusions : We clinically demonstrated our novel riboflavin conjugate photoactivated by UVA is powerful in restoring corneal integrity, without compromising the corneal endothelium. Further studies are ongoing to evaluate this approach in a clinical setting.

This abstract was presented at the 2019 ARVO Annual Meeting, held in Vancouver, Canada, April 28 - May 2, 2019.

 

An established infectious corneal ulceration in a rabbit cornea before the treatment with the riboflavin conjugate + UVA

An established infectious corneal ulceration in a rabbit cornea before the treatment with the riboflavin conjugate + UVA

 

Eight days after one 15-min application of the new riboflavin conjugate + UVA. Corneal integrity and transparency have been restored in eight days after one single application

Eight days after one 15-min application of the new riboflavin conjugate + UVA. Corneal integrity and transparency have been restored in eight days after one single application

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×